Bachem Ag | FDA | Inspections | Form 483 | Warning Letters | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Bachem AG
FDA

Bachem-PSE

Inside Manufacturing at Bachem – A Day with Ronja Otter

13 Jan 2025

// PRESS RELEASE

How to Choose the Right CDMO Partner: Key Factors to Consider

20 Nov 2024

// PRESS RELEASE

Bachem’s Sustainable TIDES Manufacturing

30 Oct 2024

// PRESS RELEASE

Data Compilation
#PharmaFlow

Bachem

Contact Supplier

Swiss RNA Therapeutics

Attending

Book a meeting

envelop Contact Supplier

Latest Content by PharmaCompass

radio-compass-blog/fda-approves-four-oligonucleotide-therapies-in-2023-novartis-gsk-novo-bet-big

Bachem AG

VISIT THE VIRTUAL BOOTH, Contact Details

VISIT THE VIRTUAL BOOTH
Review portfolio & marketing content
CONTACT DETAILS
Google Map, LinkedIn, Emails...

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

Product List 2025, Corporate Presentation, Quality Grade Building Blocks, Cosmetic Peptides, Commerical Peptide NCE, Pioneering Sustainable, Large-Scale Tides Manufacturing, Maintaining a Resilient Tides Supply Chain Under VUCA Conditions, Scientific Expertise to Spring 2024 Conferences, Leading the Octreotide Scale-up, Oligo Therapeutics 2024, Innovations for Tides 2024, GMP Certificate 2023, Gorerelin Leuprorelin Triptorelin 2024, Commercial Peptide NCE 2024, Molecular Hiving™ Technology, Semaglutide 2024, Lanreotide, Back to Stirred Vessels & On to Metric Tons of Oligonucleotides, Increasing Sustainability in Large Scale Peptide API Purification, Solid Phase Peptide Synthesis 2023, Purification- A Bottleneck for Oligonucleotide API Manufacturing, Manufacturing Complex Peptide APIs, Interview with Gilles Parmentier, Leadership Perspectives: Embracing Equity on Women’s Day, Annual General Meeting 2023

Product List 2025
Corporate Presentation
Quality Grade Building Blocks
Cosmetic Peptides
Commerical Peptide NCE
Pioneering Sustainable, Large-Scale Tides Manufacturing
Maintaining a Resilient Tides Supply Chain Under VUCA Conditions
Scientific Expertise to Spring 2024 Conferences
Leading the Octreotide Scale-up
Oligo Therapeutics 2024
Innovations for Tides 2024
GMP Certificate 2023
Gorerelin Leuprorelin Triptorelin 2024
Commercial Peptide NCE 2024
Molecular Hiving™ Technology
Semaglutide 2024
Lanreotide
Back to Stirred Vessels & On to Metric Tons of Oligonucleotides
Increasing Sustainability in Large Scale Peptide API Purification
Solid Phase Peptide Synthesis 2023
Purification- A Bottleneck for Oligonucleotide API Manufacturing
Manufacturing Complex Peptide APIs
Interview with Gilles Parmentier
Leadership Perspectives: Embracing Equity on Women’s Day
Annual General Meeting 2023

VIDEO(s)

Innovation for Peptide & Oligonucleotide Manufacturing, Peptide-based In Vitro Diagnostics, Generic APIs-Liraglutide & Other GLP-1 Analogues, Oligonucleotide Facility Virtual Tour, Semaglutide, Leading by Experience in Generic API, Customer Testimonial, Continuous Chromatography of Peptides, Expanding into Oligos - Interview, Thiazine Formation: Elucidation of Thiol-Maleimide Side-Reaction, Oligonucleotides - Innovation that Transforms Lives, Interview with Torsten Wohr, The Perfect Ingredients for a Better World, Sherpany and Futurae

Innovation for Peptide & Oligonucleotide Manufacturing
Peptide-based In Vitro Diagnostics
Generic APIs-Liraglutide & Other GLP-1 Analogues
Oligonucleotide Facility Virtual Tour
Semaglutide
Leading by Experience in Generic API
Customer Testimonial
Continuous Chromatography of Peptides
Expanding into Oligos - Interview
Thiazine Formation: Elucidation of Thiol-Maleimide Side-Reaction
Oligonucleotides - Innovation that Transforms Lives
Interview with Torsten Wohr
The Perfect Ingredients for a Better World
Sherpany and Futurae

DIGITAL CONTENT

39 CORPORATE CONTENT #SupplierSpotlight, 2 DATA COMPILATION #PharmaFlow, 123 NEWS #PharmaBuzz

39 CORPORATE CONTENT #SupplierSpotlight
2 DATA COMPILATION #PharmaFlow
123 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

45 All APIs, 36 USDMF, 13 CEP/COS, 12 JDMF, 10 KDMF, 46 NDC API, 3 VMF, 23 Listed APIs

45 All APIs
36 USDMF
13 CEP/COS
12 JDMF
10 KDMF
46 NDC API
3 VMF
23 Listed APIs

KEY PRODUCTS

Atosiban, Bivalirudin, Glucagon, Glucagon Hydrochloride, Goserelin Acetate, Lanreotide Acetate, Leuprolide Acetate, Leuprolide Mesylate, Octreotide Acetate, Propofol, Semaglutide, Teriparatide, Teriparatide Acetate, Triptorelin Acetate, Triptorelin Pamoate

Atosiban
Bivalirudin
Glucagon
Glucagon Hydrochloride
Goserelin Acetate
Lanreotide Acetate
Leuprolide Acetate
Leuprolide Mesylate
Octreotide Acetate
Propofol
Semaglutide
Teriparatide
Teriparatide Acetate
Triptorelin Acetate
Triptorelin Pamoate

SERVICES

Analytical, API Manufacturing, API & Drug Product Development

Analytical
- 1 Analytical Method Development
API Manufacturing
API & Drug Product Development
- 3 API Development

KEY SERVICES

Custom Peptide Synthesis, CMO for Peptide & Oligonucleotide APIs

Custom Peptide Synthesis
CMO for Peptide & Oligonucleotide APIs

INSPECTIONS & REGISTRATIONS

33 FDA, 3 EDQM, 5 GDUFA, 8 Others

33 FDA
3 EDQM
5 GDUFA
8 Others

Xls

Filters

Reset all filters

Filters

FILTER :

filter Legal Name Reset all filters

33 All

01 3Bachem AG

02 26Bachem Americas, Inc.

03 4Bachem SA- Branch Vionnaz

filter District Decision Reset all filters

33 All

01 15No Action Indicated

02 18Voluntary Action Indicated

filter Inspection End Date Reset all filters

33 All

01 12023-03-27

02 12022-02-23

03 22019-12-13

04 22019-06-12

05 12019-02-05

06 12018-09-21

07 22018-05-18

08 12017-11-17

09 12016-07-01

10 22016-02-25

11 22014-11-07

12 12014-02-14

13 12013-01-31

14 22013-01-28

15 22012-01-20

16 22011-06-14

17 22011-06-02

18 12010-09-29

19 22010-05-06

20 12010-04-22

21 32010-03-10

filter City Reset all filters

33 All

01 3Bubendorf

02 20Torrance

03 4Vionnaz

04 6Vista

filter Country/Area Reset all filters

33 All

01 7CH

02 26US

Supplier Virtual Booth

price-trend

01

FDA Audited

USA

Swiss RNA Therapeutics

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

District Decision : No Action Indicated

Inspection End Date : 2017-11-17

City : Bubendorf

State :

Country/Area : CH

Zip :

District :

Center :

Project Area : Drug Quality Assurance

District Decision : No Action Indicated

Inspection End Date : 2017-11-17

Bachem company banner

Product
Web Link

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

FDA Audited

USA

Swiss RNA Therapeutics

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

District Decision : Voluntary Action Indicated

Inspection End Date : 2016-02-25

City : Torrance

State : California

Country/Area : US

Zip : 90505

District :

Center :

Project Area : Monitoring of Marketed Animal Dr...

District Decision : Voluntary Action Indicated

Inspection End Date : 2016-02-25

Bachem company banner

Product
Web Link

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

03

FDA Audited

USA

Swiss RNA Therapeutics

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

District Decision : No Action Indicated

Inspection End Date : 2019-02-05

City : Vista

State : California

Country/Area : US

Zip : 92081

District :

Center :

Project Area : Drug Quality Assurance

District Decision : No Action Indicated

Inspection End Date : 2019-02-05

Bachem company banner

Product
Web Link

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

04

FDA Audited

USA

Swiss RNA Therapeutics

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

District Decision : Voluntary Action Indicated

Inspection End Date : 2014-11-07

City : Torrance

State : California

Country/Area : US

Zip : 90505

District :

Center :

Project Area : Monitoring of Marketed Animal Dr...

District Decision : Voluntary Action Indicated

Inspection End Date : 2014-11-07

Bachem company banner

Product
Web Link

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

05

FDA Audited

USA

Swiss RNA Therapeutics

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

District Decision : Voluntary Action Indicated

Inspection End Date : 2019-12-13

City : Torrance

State : California

Country/Area : US

Zip : 90505

District :

Center :

Project Area : Drug Quality Assurance

District Decision : Voluntary Action Indicated

Inspection End Date : 2019-12-13

Bachem company banner

Product
Web Link

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

06

FDA Audited

USA

Swiss RNA Therapeutics

Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

District Decision : Voluntary Action Indicated

Inspection End Date : 2016-07-01

City : Vionnaz

State :

Country/Ar